

Basingstoke, Southampton and Winchester

District Prescribing Committee (DPC)

Recommendations of the meeting of 9 June 2015

Supported or limited support e.g. Specialist recommendation

- **Dulaglutide** – the Committee supported the availability locally of dulaglutide (Trulicity) ONCE WEEKLY injection. This new GLP-1 analogue should not be seen as the routine first choice of GLP- 1 analogue because of its higher cost. More cost effective alternatives should be considered whenever possible, options include:
 - Daily Administration: exenatide (Byetta) twice daily, lixisenatide (Lyxumia) or liraglutide (Victoza) (maximum 1.2mg) daily,
 - Weekly Administration: exenatide (Bydureon).
- Dulaglutide may be considered as the second line choice to liraglutide for patients with mild to moderate renal impairment, and may be of benefit for patients with compliance problems, such as dexterity, with other devices or dosing regimens. (Local GLP-1 decision guide to follow)

The Committee will consider its recommendations on GLP-1 analogues when NICE issues its updated clinical guidelines in the autumn.

Other Information/ Reminders

- **Melatonin Shared Care Guidelines approved:** New shared care guidelines for the use of melatonin for sleep disorders / difficulties in children have been developed in conjunction with local specialists. Note that the guidelines recommend that melatonin MR tablets 2mg (Circadin®) is the first line melatonin product as it has a UK product license (note its use in children is off-label). The guidelines are available at: <http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/shared-care-guidelines/1100-melatonin-shared-care-guidelines-gp-summary-2014-updated-may-2015/file>
- **Denosumab shared care guidelines:** these guidelines have been updated and are available at: <http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/shared-care-guidelines/1144-denosumab-shared-care-guideline-gp-summary-updated-24-june-2015/file>
- **Chronic non-malignant pain disease guidelines:** the local chronic non-malignant pain guidelines are being updated and should be available following the Committee meeting in August.
- **Review of new inhalers for COPD:** there have recently been a number of new inhalers launched for the treatment of COPD. Guidance on the appropriate use of these products is being developed in conjunction with local specialists and will be available following the Committee meeting in August.

Summarised on behalf of the District Prescribing Committee

Neil Hardy (West Hampshire CCG) 05.07.15